FATE THERAPEUTICS INC (FATE) research
FATE THERAPEUTICS INC- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $2.32
- As of
FATE THERAPEUTICS INC (FATE): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-28.
As of . Source: SEC EDGAR filings for FATE. Method and limitations.
Share the FATE intelligence card
See the full FATE dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for FATE on one page. Preview it with sample data, then open it live with a free account.
Preview the FATE dossierActive signals for FATE
- highCONSENSUS_BUY
3 tracked funds increased FATE this 2026Q2, institutional consensus
- highINSTITUTIONAL_SURGE
Point72 Asset Management, L.P. added +926% to FATE (2026Q2)
- highINSTITUTIONAL_SURGE
MILLENNIUM MANAGEMENT LLC added +366% to FATE (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 69% of FATE (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +171% to FATE (2026Q2)
FREE, NO ACCOUNT
Every signal on FATE, as it fires
You are seeing 5 of 13 signals recorded on FATE since 2026-05-16.
The five above landed across 2 days. The other 8 were recorded on 4 other days. 7 of the 13 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in FATE (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| TWO SIGMA INVESTMENTS, LPCUSIP 31189P102 · 2026Q2 | $9.7M | 0.01% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 31189P102 · 2026Q2 | $8.1M | 0.01% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 31189P102 · 2026Q2 | $6.6M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 31189P102 · 2026Q2 | $2.7M | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 31189P102 · 2026Q2 | $1.2M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, FATE
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
FATE against its peers
FATE's operating margin of -2222.4% ranks in the 17th percentile of 14 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-05-31.
| Metric | FATE | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 6.6M USD | 12.6M USD | 44 | 16 |
| Operating margin | -2222.4% | -699.8% | 17 | 14 |
| Net margin | -2051.1% | -529.8% | 28 | 15 |
| Return on equity | -65.8% | -41.4% | 40 | 20 |
Peers (23): IKT, UPB, XFOR, QTTB, EYPT, CYDY, RCKT, SABS, ACIU, ABEO, GLSI, IPSC, IMRX, VNDA, STRO, LXEO, PRLD, NWBO, ANIK, EVMN, IFRX, CAMP, PALI. Left out: VCRE (no annual filing), CUVL (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-05-31. Every figure is one full fiscal year read from one annual filing (FATE: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more FATE signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to FATEand get the insider, 13F, options, and confluence read in one view.